Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$272.00
+1.8%
$267.43
$199.90
▼
$290.25
$654.79B0.227.94 million shs1.81 million shs
Novartis AG stock logo
NVS
Novartis
$151.94
+0.5%
$150.19
$125.88
▼
$170.46
$290.32B0.42.01 million shs317,428 shs
Roche Holding AG stock logo
RHHBY
Roche
$58.89
-0.2%
$56.99
$47.05
▼
$61.75
$375.16B0.42.11 million shs117,589 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-2.10%-5.88%+2.93%-1.36%+31.51%
Novartis AG stock logo
NVS
Novartis
-2.49%-5.51%-1.47%-4.85%+18.88%
Roche Holding AG stock logo
RHHBY
Roche
-0.87%-2.48%-0.19%+1.55%+21.55%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$272.00
+1.8%
$267.43
$199.90
▼
$290.25
$654.79B0.227.94 million shs1.81 million shs
Novartis AG stock logo
NVS
Novartis
$151.94
+0.5%
$150.19
$125.88
▼
$170.46
$290.32B0.42.01 million shs317,428 shs
Roche Holding AG stock logo
RHHBY
Roche
$58.89
-0.2%
$56.99
$47.05
▼
$61.75
$375.16B0.42.11 million shs117,589 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-2.10%-5.88%+2.93%-1.36%+31.51%
Novartis AG stock logo
NVS
Novartis
-2.49%-5.51%-1.47%-4.85%+18.88%
Roche Holding AG stock logo
RHHBY
Roche
-0.87%-2.48%-0.19%+1.55%+21.55%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.73
Moderate Buy$275.923.33% Upside
Novartis AG stock logo
NVS
Novartis
2.17
Hold$152.250.60% Upside
Roche Holding AG stock logo
RHHBY
Roche
2.57
Moderate Buy$60.001.69% Upside

Current Analyst Ratings Breakdown

Latest JNJ, RHHBY, and NVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/4/2026
Novartis AG stock logo
NVS
Novartis
DowngradeBuy (B) ➝ Buy (B-)
11/2/2026
Roche Holding AG stock logo
RHHBY
Roche
DowngradeStrong-Buy ➝ Hold
10/30/2026
Novartis AG stock logo
NVS
Novartis
DowngradeHold ➝ Sell
10/28/2026
Novartis AG stock logo
NVS
Novartis
Reiterated RatingSector Perform
10/28/2026
Novartis AG stock logo
NVS
Novartis
Reiterated RatingNeutral
10/28/2026
Novartis AG stock logo
NVS
Novartis
Reiterated RatingOverweight$163.00
10/28/2026
Novartis AG stock logo
NVS
Novartis
Initiated CoverageHold
10/23/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
DowngradeBuy (B+) ➝ Buy (B-)
10/23/2026
Roche Holding AG stock logo
RHHBY
Roche
UpgradeHold ➝ Buy
10/22/2026
Novartis AG stock logo
NVS
Novartis
Reiterated RatingBuy (B)
10/21/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
DowngradeBuy ➝ Hold
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B6.82$13.83 per share19.31$33.87 per share7.88
Novartis AG stock logo
NVS
Novartis
$54.53B5.30$10.47 per share14.45$19.69 per share7.69
Roche Holding AG stock logo
RHHBY
Roche
$76.45B4.92$3.57 per share16.53$7.18 per share8.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$6.6040.4623.182.7416.20%31.64%13.04%1/26/2027 (Estimated)
Novartis AG stock logo
NVS
Novartis
$13.98B$5.2428.8815.152.8418.11%41.04%14.45%2/3/2027 (Estimated)
Roche Holding AG stock logo
RHHBY
Roche
$15.55BN/AN/A18.103.69N/AN/AN/A1/28/2027 (Estimated)

Latest JNJ, RHHBY, and NVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/27/2026Q3 2026
Novartis AG stock logo
NVS
Novartis
$2.25$2.46+$0.21$0.63$14.53 billion$15.03 billion
10/13/2026Q3 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.53$2.59+$0.06$0.09$25.38 billion$25.40 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.361.97%+5.25%81.21%64 Years
Novartis AG stock logo
NVS
Novartis
$3.082.03%+5.28%58.78%N/A
Roche Holding AG stock logo
RHHBY
Roche
$0.971.65%N/AN/AN/A

Latest JNJ, RHHBY, and NVS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/13/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.15%11/24/202611/24/202612/8/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.44
1.02
0.74
Novartis AG stock logo
NVS
Novartis
0.98
0.88
0.70
Roche Holding AG stock logo
RHHBY
Roche
0.69
1.23
0.95

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Novartis AG stock logo
NVS
Novartis
13.12%
Roche Holding AG stock logo
RHHBY
Roche
N/A

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Novartis AG stock logo
NVS
Novartis
0.01%
Roche Holding AG stock logo
RHHBY
Roche
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable
Novartis AG stock logo
NVS
Novartis
75,2671.91 billion1.91 billionOptionable
Roche Holding AG stock logo
RHHBY
Roche
103,2496.37 billionN/ANot Optionable

Recent News About These Companies

RHHBY Secures FDA Approval for Breast Cancer Treatment
Roche’s breast cancer pill Wilserdly approved in the U.S.
Roche nets de novo nod for automated mass spec assay

New MarketBeat Followers Over Time

Media Sentiment Over Time

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$272.00 +4.86 (+1.82%)
As of 10:48 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Novartis stock logo

Novartis NYSE:NVS

$151.94 +0.72 (+0.48%)
As of 10:48 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Roche stock logo

Roche OTCMKTS:RHHBY

$58.89 -0.11 (-0.19%)
As of 10:29 AM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.